Analysis of Open Targets and other databases indicated evidence of drug development, including phase II-IV trials, for 6 proteins (PGF, ASGR1, F2R, TFPI, tenascin, and MMP3), with 3 related to CVD outcomes or traits (F2R for MI, TFPI for ICH, and ASGR1 for familial hypercholesterolemia) (Table 2). Here, ASGR1 is linked to familial hypercholesterolemia.